EUVIMEDEUVIMED entdecken
Crossref

Spatial tertiary lymphoid structures imply response to anti‐ PD ‐1 plus anlotinib in advanced non‐small cell lung cancer

Jianli Ma, Yuwei Deng, Minghui Zhang, Qingyuan Zhang iD

Immunology · 2024-11 · 173 (3) · 536-551

DOI: 10.1111/imm.13841 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunology, online erschienen am 30.07.2024. Verfasst von Jianli Ma und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang Province, People's Republic of China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Indoles, Quinolines. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite breakthroughs of immunotherapy synergistically combined with blockade of vascular endothelial growth factor receptor, several patients with advanced non‐small cell lung cancer (NSCLC) experience non‐response or followed relapse. Organized lymphoid aggregates, termed tertiary lymphoid structures (TLSs), are found to be associated with improved response to immunotherapy. Here, we explore the landscapes of TLSs in tumour tissues from a real‐world retrospective study. Our investigation showed that with a median follow‐up of 11.2 months, the ORR was 28.6% (18/63, 95% CI 17.9–41.3) and the median PFS was 6.1 (95% CI 5.5–6.6) months in NSCLC patients treated with PD‐1 blockade combined with anlotinib. By multiplex immunofluorescence (mIF) analysis, spatially, more TLSs and high CD20+ B‐cell ratio in TLSs were associated with higher ORR. High density of intratumoral CD8+ T cells showed better ORR and PFS. The numbers of CD8+ T cells with a distance within 20 μm and 20–50 μm between tumour cells were higher in responders than non‐responders. But responders had significantly higher TLSs within 20 μm rather than within 20–50 μm of tumour cells than non‐responders. The inflamed immunophenotyping occupied higher proportions in responders and was associated with better PFS. Besides, tumour cells in non‐responders were found more temporal cell‐in‐cell structures than responders, which could protect inner cells from T‐cell attacks. Taken together, landscape of TLSs and proximity architecture may imply superior responses to PD‐1 blockade combined with anlotinib for patients with advanced non‐small cell lung cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsIndolesQuinolinesProgrammed Cell Death 1 ReceptorImmune Checkpoint InhibitorsTertiary Lymphoid StructuresHumansMaleFemaleMiddle AgedAgedRetrospective StudiesAntineoplastic Combined Chemotherapy ProtocolsCD8-Positive T-LymphocytesLymphocytes, Tumor-InfiltratingTreatment OutcomeTumor MicroenvironmentAdultAged, 80 and over

Stichwörter der Autor:innen

PD‐1 blockadeadvanced non‐small cell lung canceranlotinibcell‐in‐cell structurestertiary lymphoid structure

Substanzen

anlotinibIndolesQuinolinesProgrammed Cell Death 1 ReceptorImmune Checkpoint InhibitorsPDCD1 protein, human

Autor:innen und Institutionen

  • Department of Radiation Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang Province, People's Republic of China.
  • Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang Province, People's Republic of China.

ORCID-Profile: Qingyuan Zhang

Zitieren

APA

Ma, J., Deng, Y., Zhang, M., & Zhang, Q. (2024). Spatial tertiary lymphoid structures imply response to anti‐ PD ‐1 plus anlotinib in advanced non‐small cell lung cancer. Immunology, 173(3), 536-551. https://doi.org/10.1111/imm.13841

Vancouver

Ma J, Deng Y, Zhang M, Zhang Q. Spatial tertiary lymphoid structures imply response to anti‐ PD ‐1 plus anlotinib in advanced non‐small cell lung cancer. Immunology. 2024;173(3):536-551. doi:10.1111/imm.13841

BibTeX
@article{Ma2024,
  author = {Ma, Jianli and Deng, Yuwei and Zhang, Minghui and Zhang, Qingyuan},
  title = {Spatial tertiary lymphoid structures imply response to anti‐ PD ‐1 plus anlotinib in advanced non‐small cell lung cancer},
  journal = {Immunology},
  year = {2024},
  volume = {173},
  number = {3},
  pages = {536--551},
  doi = {10.1111/imm.13841}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche